 |
|
|
|
 |
|
|
| Article 1 to 10 out of 34 concerning Merck & Co., Inc.
|
-
Global Vaccine Market Forecast to 2012
(09 Oct 2008)
Examine This Global Vaccine Market Forecast to 2012 as the Market is Expected to Emerge as the Fastest Growing Therapy Area in the Next 5 Years
Research and Markets has announced the addition of the "Global Vaccine Market Forecast to 2012" report to their offering."Global Vaccine Market Forecast to 2012”, our new research report, states that vaccines, which were earlier thought as a low ...
-
Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
(20 Jun 2008)
Nuevolution A/S announced that it has entered into a drug discovery collaboration with Merck & Co. Inc. Nuevolution will apply its proprietary Chemetics® drug discovery technology to identify novel small molecule leads against several drug targets ...
-
NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients
(14 May 2008)
NicOx S.A. announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies' collaborative agreement to develop new nitric oxide-donating antihypertensive...
-
Addex Achieves First Milestone in Parkinson's Disease Collaboration with Merck & Co., Inc.
(27 Feb 2008)
Collaboration Targets a Non-Dopaminergic Approach to Treating Parkinson's Disease
Addex Pharmaceuticals announced that the first preclinical milestone has been achieved in a recently announced exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme Research Ltd). The ...
-
Intercell Receives Milestone Payment From Merck & Co. Inc
(18 Dec 2007)
Milestone Payment Triggered By Initiation Of Phase II Clinical Trial of Investigational Vaccine to Prevent S. aureus Infection
Intercell AG announced progress in its collaboration with Merck & Co., Inc. to develop a vaccine to prevent Staphylococcus aureus, (S. aureus), infection. Merck has initiated a Phase II clinical trial designed to evaluate the efficacy and safety of ...
-
Addex and Merck & Co., Inc. Collaborate to Develop Drugs for Parkinson's Disease
(04 Dec 2007)
Collaboration Targets a Non-Dopaminergic Approach to Treating Parkinson's Disease
Addex Pharmaceuticals announced that it has entered an exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme Research Ltd) with the goal of developing a new class of orally available drugs, ...
-
Crucell grants Merck & Co., Inc. access to vaccine technology
(11 Sep 2007)
Crucell N.V. announced that Merck & Co., Inc. has exercised an option for the exclusive use of Crucell's PER.C6® technology and an option for access to Crucell's AdVac® vaccine technology in two infectious disease areas.Dr. Jaap Goudsmit, Crucell's ...
-
Merck & Co., Inc. Opens Asia Pacific Regional Headquarters in Singapore
(23 Aug 2007)
Merck & Co., Inc, operating in Asia Pacific under the corporate name, Merck Sharp & Dohme (MSD), announced it has opened its regional headquarters in Singapore at Parkview Square. The move is part of the Company's global strategy to strengthen its ...
-
Staphylococcus aureus vaccine development on track safe and immunogenic in Phase I clinical trials
(22 May 2007)
Intercell AG has been informed by its strategic partner Merck & Co., Inc. on the results of a Phase I study involving in total over 120 adult healthy volunteers comparing safety and immunogenicity of different doses of the Staphylococcus aureus ...
-
Merck & Co., Inc. and Crucell Sign Cross-licensing Agreement on Vaccine Production Technology
(03 Jan 2007)
Crucell N.V. announced that it has signed a cross-licensing agreement with Merck & Co., Inc. In addition to previously licensed rights to PER.C6, the agreement opens the way for Merck to use Crucell technology on an exclusive basis in additional ...
|
|
|
|
|
Top
